The advent of anti-VEGF therapy has fundamentally changed how specialists manage vision-threatening retinal conditions. Consequently, these agents target specific bio-active molecules responsible for abnormal vascular growth. Specifically, they treat diabetic macular edema (DME), choroidal neovascular membranes (CNVM), and retinal vein occlusion complications. Initially, clinicians relied on bevacizumab and ranibizumab, but newer options like aflibercept and brolucizumab have expanded the toolkit. Furthermore, the recent introduction of faricimab offers a dual-action mechanism to stabilize retinal vasculature more effectively.

Optimizing Clinical Outcomes with Anti-VEGF Therapy

Clinicians in India now use various dosing regimens to balance efficacy and treatment burden. For instance, the "treat-and-extend" model allows for individualized injection intervals based on anatomical stability. Alternatively, the "pro-re-nata" approach triggers retreatment only when disease activity recurs. Additionally, biosimilars now provide cost-effective alternatives for patients facing significant financial barriers. Indeed, biosimilar ranibizumab has shown comparable safety and efficacy in large Indian cohorts, significantly improving treatment adherence.

Future Directions and Durability

Researchers are currently developing next-generation agents with greater durability and potency. Specifically, sustained-release systems like biodegradable depots might soon eliminate the need for frequent clinical visits. Moreover, port delivery systems offer continuous medication release into the vitreous over several months. Finally, long-term studies continue to refine our understanding of safety and visual optimization. Thus, the future of retinal care looks increasingly patient-centric, accessible, and durable.

Frequently Asked Questions

What are the primary indications for anti-VEGF therapy?

Doctors primarily use these agents for diabetic macular edema, neovascular glaucoma, retinopathy of prematurity, and macular edema secondary to retinal vein occlusion.

How do biosimilars benefit patients in India?

Biosimilars offer a 30% to 50% reduction in treatment costs. This price shift improves affordability and ensures that more patients can complete their prescribed long-term therapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Kannan NB et al. Anti-vascular endothelial growth factors in retinal and choroidal diseases - Present landscape. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3149_25. PMID: 42060355.

2. Sharma A et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol. 2023;71(2):352-354.

3. Biswas et al. Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study). Clinical Ophthalmology. 2025;19:3881-3887.